These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
325 related articles for article (PubMed ID: 20965712)
21. Anti-inflammatory effects of combined budesonide/formoterol in COPD exacerbations. Bathoorn E; Liesker JJ; Postma DS; Boorsma M; Bondesson E; Koëter GH; Kauffman HF; van Oosterhout AJ; Kerstjens HA COPD; 2008 Oct; 5(5):282-90. PubMed ID: 18972276 [TBL] [Abstract][Full Text] [Related]
22. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD. Kuna P; Jenkins M; O'Brien CD; Fahy WA Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578 [TBL] [Abstract][Full Text] [Related]
23. Once versus twice daily formoterol via Novolizer for patients with moderate to severe COPD--a double-blind, randomised, controlled trial. Welte T; Metzenauer P; Hartmann U Pulm Pharmacol Ther; 2008; 21(1):4-13. PubMed ID: 17101285 [TBL] [Abstract][Full Text] [Related]
24. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial. Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048 [TBL] [Abstract][Full Text] [Related]
25. Rapid onset of bronchodilation with formoterol/beclomethasone Modulite and formoterol/budesonide Turbuhaler as compared to formoterol alone in patients with COPD. Cazzola M; Pasqua F; Ferri L; Biscione G; Cardaci V; Matera MG Pulm Pharmacol Ther; 2011 Feb; 24(1):118-22. PubMed ID: 20816833 [TBL] [Abstract][Full Text] [Related]
26. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045 [TBL] [Abstract][Full Text] [Related]
27. Total reversibility testing as indicator of the clinical efficacy of formoterol in COPD. Molimard M; Bourcereau J; Le Gros V; Bourdeix I Respir Med; 2005 Jun; 99(6):695-702. PubMed ID: 15878485 [TBL] [Abstract][Full Text] [Related]
28. Efficacy of budesonide/formoterol pressurized metered-dose inhaler versus budesonide pressurized metered-dose inhaler alone in Hispanic adults and adolescents with asthma: a randomized, controlled trial. Zangrilli J; Mansfield LE; Uryniak T; O'Brien CD Ann Allergy Asthma Immunol; 2011 Sep; 107(3):258-65.e2. PubMed ID: 21875546 [TBL] [Abstract][Full Text] [Related]
29. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma. O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333 [TBL] [Abstract][Full Text] [Related]
30. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients. Dusser D; Vicaut E; Lefrançois G; Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009 [TBL] [Abstract][Full Text] [Related]
31. A trial of beclomethasone/formoterol in COPD using EXACT-PRO to measure exacerbations. Singh D; Kampschulte J; Wedzicha JA; Jones PW; Cohuet G; Corradi M; Higenbottam T; Petruzzelli S; Vestbo J Eur Respir J; 2013 Jan; 41(1):12-7. PubMed ID: 22653766 [TBL] [Abstract][Full Text] [Related]
32. Relative effectiveness of budesonide/formoterol and fluticasone propionate/salmeterol in a 1-year, population-based, matched cohort study of patients with chronic obstructive pulmonary disease (COPD): Effect on COPD-related exacerbations, emergency department visits and hospitalizations, medication utilization, and treatment adherence. Blais L; Forget A; Ramachandran S Clin Ther; 2010 Jul; 32(7):1320-8. PubMed ID: 20678680 [TBL] [Abstract][Full Text] [Related]
33. Budesonide/formoterol as effective as prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-group, multicentre study. Ställberg B; Selroos O; Vogelmeier C; Andersson E; Ekström T; Larsson K Respir Res; 2009 Feb; 10(1):11. PubMed ID: 19228428 [TBL] [Abstract][Full Text] [Related]
34. Extrafine beclomethasone/formoterol in severe COPD patients with history of exacerbations. Wedzicha JA; Singh D; Vestbo J; Paggiaro PL; Jones PW; Bonnet-Gonod F; Cohuet G; Corradi M; Vezzoli S; Petruzzelli S; Agusti A; Respir Med; 2014 Aug; 108(8):1153-62. PubMed ID: 24953015 [TBL] [Abstract][Full Text] [Related]
35. Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. Kerwin EM; Siler TM; Arora S; Darken P; Rose E; Reisner C Int J Chron Obstruct Pulmon Dis; 2018; 13():1483-1494. PubMed ID: 29773947 [TBL] [Abstract][Full Text] [Related]
36. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler. Berger WE; Noonan MJ J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601 [TBL] [Abstract][Full Text] [Related]
37. EXCEL: A randomised trial comparing salmeterol/fluticasone propionate and formoterol/budesonide combinations in adults with persistent asthma. Dahl R; Chuchalin A; Gor D; Yoxall S; Sharma R Respir Med; 2006 Jul; 100(7):1152-62. PubMed ID: 16675212 [TBL] [Abstract][Full Text] [Related]
38. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Tashkin DP; Littner M; Andrews CP; Tomlinson L; Rinehart M; Denis-Mize K Respir Med; 2008 Apr; 102(4):479-87. PubMed ID: 18258423 [TBL] [Abstract][Full Text] [Related]
39. Formoterol as dry powder oral inhalation compared with salbutamol metered-dose inhaler in acute exacerbations of chronic obstructive pulmonary disease. Cazzola M; D'Amato M; Califano C; Di Perna F; Calderaro E; Matera MG; D'Amato G Clin Ther; 2002 Apr; 24(4):595-604. PubMed ID: 12017404 [TBL] [Abstract][Full Text] [Related]
40. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Singh D; Papi A; Corradi M; Pavlišová I; Montagna I; Francisco C; Cohuet G; Vezzoli S; Scuri M; Vestbo J Lancet; 2016 Sep; 388(10048):963-73. PubMed ID: 27598678 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]